Extent of myometrial invasion

<50%

17

(34%)

15

(88.2%)

2

(11.8%)

<0.001^‡

15

(88.2%)

2

(11.8%)

<0.001^‡

>50%

33

(66%)

7

(21.2%)

26

(78.8%)

6

(18.2%)

27

(81.8%)

Cervical stromal invasion

Absent

22

(44%)

17

(77.3%)

5

(22.7%)

0.005^‡

17

(77.3%)

5

(22.7%)

0.007^‡

Present

28

(56%)

5

(17.9%)

23

(82.1%)

4

(14.3%)

24

(85.7%)

Parametrial extension

Absent

32

(64%)

19

(59.4%)

13

(40.6%)

0.003^‡

19

(59.4%)

13

(40.6%)

0.009^‡

Present

18

(36%)

3

(16.7%)

15

(83.3%)

2

(11.1%)

16

(88.9%)

Serosal invasion

Absent

32

(64%)

19

(59.4%)

13

(40.6%)

0.049^‡

19

(59.4%)

13

(40.6%)

0.043^‡

Present

18

(36%)

3

(16.7%)

15

(83.3%)

2

(11.1%)

16

(88.9%)

Adnexal invasion

Absent

32

(64%)

21

(65.6%)

11

(34.4%)

0.03^‡

21

(65.6%)

11

(34.4%)

0.02^‡

Present

18

(36%)

1

(5.6%)

17

(94.4%)

0

(0%)

18

(100%)

Peritoneal cytology

Negative

30

(60%)

19

(63.3%)

11

(36.7%)

0.006^‡

19

(63.3%)

11

(36.7%)

0.004^‡

Positive

20

(40%)

3

(15%)

17

(85%)

2

(10%)

18

(90%)

Lymph node

Negative

30

(60%)

19

(63.3%)

11

(36.7%)

0.009^‡

19

(63.3%)

11

(36.7%)

0.003^‡

Positive

20

(40%)

3

(15%)

17

(85%)

2

(10%)

18

(90%)

Distant metastasis

Negative

40

(80%)

21

(52.2%)

19

(47.5%)

0.029^‡

21

(52.5%)

19

(47.5%)

0.003^‡

Positive

10

(20%)

1

(10%)

9

(90%)

0

(0%)

10

(100%)

FIGO stage

Stage I

22

(44%)

17

(77.3%)

5

(22.7%)

<0.001^§

17

(77.3%)

5

(22.7%)

<0.001^§

Stage II

10

(20%)

2

(20%)

8

(80%)

2

(20%)

8

(80%)

Stage III

8

(16%)

2

(25%)

6

(75%)

2

(25%)

6

(75%)

Stage IV

10

(20%)

1

(10%)

9

(90%)

1

(10%)

9

(90%)

CRKL

Low

22

(44%)

20

(90.9%)

2

(9.1%)

<0.001^‡

High

28

(56%)

1

(3.6%)

27

(96.4%)

CK2 β

Low

21

(42%)

20

(95.2%)

1

(4.8%)

<0.001^‡

High

29

(58%)

2

(6.9%)

27

(93.1%)